A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS-Mutant Non-Small Cell Lung Cancer.

MLA

Aggarwal, Charu, et al. “A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS-Mutant Non-Small Cell Lung Cancer.” Oncologist, vol. 28, no. 7, July 2023, p. 644. EBSCOhost, https://doi.org/10.1093/oncolo/oyad106.

APA

Aggarwal, C., Maity, A. P., Bauml, J. M., Long, Q., Aleman, T., Ciunci, C., D’Avella, C., Volpe, M., Anderson, E., Jones, L. M., Sun, L., Singh, A. P., Marmarelis, M. E., Cohen, R. B., Langer, C. J., & Amaravadi, R. (2023). A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS-Mutant Non-Small Cell Lung Cancer. Oncologist, 28(7), 644. https://doi.org/10.1093/oncolo/oyad106

Chicago

Aggarwal, Charu, Alisha P Maity, Joshua M Bauml, Qi Long, Tomas Aleman, Christine Ciunci, Christopher D’Avella, et al. 2023. “A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS-Mutant Non-Small Cell Lung Cancer.” Oncologist 28 (7): 644. doi:10.1093/oncolo/oyad106.